UB Paderborn / Katalog / Suche / in CDI

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers

Cancers, 2021-12, Vol.13 (23), p.6059

2021

Link zum Volltext

Clinical implications of CTNNA1 germline mutations in asymptomatic carriers

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-07, Vol.22 (4), p.899-903

2019

Link zum Volltext

Verfügbarkeit prüfen

Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTC1‐SS18 gene fusion

Journal of pathology and bacteriology, 2018-06, Vol.245 (2), p.186-196

2018

Link zum Volltext

Verfügbarkeit prüfen

Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions

Modern pathology, 2023-08, Vol.36 (8), p.100192-100192, Article 100192

2023

Link zum Volltext

Verfügbarkeit prüfen

French Brain Tumor DataBase: 5-Year Histological Results on 25 756 Cases

Brain pathology (Zurich, Switzerland), 2011-11, Vol.21 (6), p.633-644

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2− pN0 early breast cancers

Breast cancer research and treatment, 2017-10, Vol.165 (3), p.611-621

2017

Link zum Volltext

Verfügbarkeit prüfen

Histoseminar: Saved by a positive staining! About the use of diagnostic biomarkers in breast pathology: case no. 6

Annales de pathologie, 2022-07, Vol.42 (4), p.317-324

Maran-Gonzalez, Aurélie

2022

Link zum Volltext

Verfügbarkeit prüfen

PHOX2B immunolabeling: a novel tool for the diagnosis of undifferentiated neuroblastomas among childhood small round blue-cell tumors

The American journal of surgical pathology, 2012-08, Vol.36 (8), p.1141-1149

2012

Link zum Volltext

Verfügbarkeit prüfen

Histoséminaire : Ouf, c’est positif ! De l’usage salvateur des biomarqueurs en pathologie mammaire : cas no6

Annales de pathologie, 2022-07, Vol.42 (4), p.317-324

Maran-Gonzalez, Aurélie

2022

Link zum Volltext

Verfügbarkeit prüfen

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

Cancer management and research, 2019-01, Vol.11, p.10353-10373

2019

Link zum Volltext

Verfügbarkeit prüfen

HER2 overexpression a major risk factor for recurrence in pT1a‐bN0M0 breast cancer: results from a French regional cohort

Cancer medicine (Malden, MA), 2014-02, Vol.3 (1), p.134-142

2014

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Cancers, 2020-09, Vol.12 (9), p.2666

2020

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic challenges on breast needle core biopsies. Case 2: Spindle cell neoplasm

Annales de pathologie, 2017-10, Vol.37 (5), p.368-379

Maran-Gonzalez, Aurélie

2017

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic challenges on breast needle core biopsies. Case 1: Low grade fibroepithelial neoplasm

Annales de pathologie, 2017-10, Vol.37 (5), p.359-367

Maran-Gonzalez, Aurélie

2017

Link zum Volltext

Verfügbarkeit prüfen

Difficultés diagnostiques sur biopsies mammaires. Cas n o 1 : tumeur fibro-épithéliale de bas grade

Annales de pathologie, 2017-10, Vol.37 (5), p.359-367

Maran-Gonzalez, Aurélie

2017

Link zum Volltext

Verfügbarkeit prüfen

Difficultés diagnostiques sur biopsies mammaires. Cas n o 2 : tumeur à cellules fusiformes

Annales de pathologie, 2017-10, Vol.37 (5), p.368-379

Maran-Gonzalez, Aurélie

2017

Link zum Volltext

Verfügbarkeit prüfen

Difficultés diagnostiques sur biopsies mammaires. Cas no 1 : tumeur fibro-épithéliale de bas grade

Annales de pathologie, 2017-10, Vol.37 (5), p.359-367

Maran-Gonzalez, Aurélie

2017

Link zum Volltext

Verfügbarkeit prüfen

Difficultés diagnostiques sur biopsies mammaires. Cas no 2 : tumeur à cellules fusiformes

Annales de pathologie, 2017-10, Vol.37 (5), p.368-379

Maran-Gonzalez, Aurélie

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-05-05: Prognostic value of HER2 expression levels in non-metastatic triple-negative breast cancer and correlation with other biomarkers

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-05-05

2022

Link zum Volltext

Verfügbarkeit prüfen

Ouf, c’est positif ! – De l’usage des biomarqueurs en pathologie mammaire. Pré-test

Annales de pathologie, 2022-07, Vol.42 (4), p.286-288

2022

Link zum Volltext

Verfügbarkeit prüfen

Ouf, c’est positif ! – De l’usage des biomarqueurs en pathologie mammaire. Réponses au pré-test

Annales de pathologie, 2022-07, Vol.42 (4), p.289-290

2022

Link zum Volltext

Verfügbarkeit prüfen

2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France

Annales de pathologie, 2021-11, Vol.41 (6), p.507-520

2021

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant treatment of breast cancer: implications for the pathologist

Annales de pathologie, 2011-12, Vol.31 (6), p.442-454

2011

Link zum Volltext

Verfügbarkeit prüfen

Adenocarcinomas of nasal cavities and paranasal sinuses: Diagnostic pitfalls in sinonasal glandular lesions

Annales de pathologie, 2009-09, Vol.29 (4), p.286

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers

Clinical implications of CTNNA1 germline mutations in asymptomatic carriers

Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTC1‐SS18 gene fusion

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions

French Brain Tumor DataBase: 5-Year Histological Results on 25 756 Cases

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2− pN0 early breast cancers

Histoseminar: Saved by a positive staining! About the use of diagnostic biomarkers in breast pathology: case no. 6

PHOX2B immunolabeling: a novel tool for the diagnosis of undifferentiated neuroblastomas among childhood small round blue-cell tumors

Histoséminaire : Ouf, c’est positif ! De l’usage salvateur des biomarqueurs en pathologie mammaire : cas no6

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

HER2 overexpression a major risk factor for recurrence in pT1a‐bN0M0 breast cancer: results from a French regional cohort

Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Diagnostic challenges on breast needle core biopsies. Case 2: Spindle cell neoplasm

Diagnostic challenges on breast needle core biopsies. Case 1: Low grade fibroepithelial neoplasm

Difficultés diagnostiques sur biopsies mammaires. Cas n o 1 : tumeur fibro-épithéliale de bas grade

Difficultés diagnostiques sur biopsies mammaires. Cas n o 2 : tumeur à cellules fusiformes

Difficultés diagnostiques sur biopsies mammaires. Cas no 1 : tumeur fibro-épithéliale de bas grade

Difficultés diagnostiques sur biopsies mammaires. Cas no 2 : tumeur à cellules fusiformes

Abstract P1-05-05: Prognostic value of HER2 expression levels in non-metastatic triple-negative breast cancer and correlation with other biomarkers

Ouf, c’est positif ! – De l’usage des biomarqueurs en pathologie mammaire. Pré-test

Ouf, c’est positif ! – De l’usage des biomarqueurs en pathologie mammaire. Réponses au pré-test

2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France

Neoadjuvant treatment of breast cancer: implications for the pathologist

Adenocarcinomas of nasal cavities and paranasal sinuses: Diagnostic pitfalls in sinonasal glandular lesions

Suchergebnisse filtern